PDGFRB - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
NCK2	NCK adaptor protein 2	Downstream signal transduction Nephrin family interactions Ephrin signaling Activation of RAC1 VEGFA-VEGFR2 Pathway Regulation of cortical dendrite branching
NEDD4	NEDD4 E3 ubiquitin protein ligase	ISG15 antiviral mechanism Downregulation of ERBB4 signaling Regulation of PTEN localization Regulation of PTEN stability and activity Antigen processing: Ubiquitination & Proteasome degradation
PDAP1	PDGFA associated protein 1	Neutrophil degranulation
PDGFB	platelet derived growth factor subunit B	Platelet degranulation PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer Non-integrin membrane-ECM interactions RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Pegpleranib	Malignant pleural mesothelioma Glioma
PDGFD	platelet derived growth factor D	Signaling by PDGF	CR002 Tandutinib
PDGFRA	platelet derived growth factor receptor alpha	PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Imatinib-resistant PDGFR mutants Sunitinib-resistant PDGFR mutants Regorafenib-resistant PDGFR mutants Sorafenib-resistant PDGFR mutants PDGFR mutants bind TKIs	Becaplermin Imatinib Sunitinib XL820 Olaratumab Pazopanib Midostaurin Regorafenib Ponatinib Lenvatinib Nintedanib Foreskin keratinocyte (neonatal) Fostamatinib Erdafitinib Amuvatinib Ripretinib	Glioma
PIK3C2B	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta	Synthesis of PIPs at the plasma membrane	Fostamatinib
PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	PI3K Cascade IRS-mediated signalling GPVI-mediated activation cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K events in ERBB4 signaling PIP3 activates AKT signaling Signaling by SCF-KIT Synthesis of PIPs at the plasma membrane GAB1 signalosome Signaling by cytosolic FGFR1 fusion mutants Downstream signal transduction PI3K events in ERBB2 signaling PI3K/AKT activation Downstream TCR signaling Role of phospholipids in phagocytosis Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions Costimulation by the CD28 family CD28 dependent PI3K/Akt signaling G alpha (q) signalling events VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway Interleukin-3, Interleukin-5 and GM-CSF signaling Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PI3K/AKT signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer RET signaling Extra-nuclear estrogen signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Activated NTRK2 signals through PI3K Interleukin receptor SHC signaling Regulation of signaling by CBL Regulation of signaling by CBL Activated NTRK3 signals through PI3K FLT3 Signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants	ATP Caffeine XL765 Wortmannin Pilaralisib Alpelisib Copanlisib	Ovarian cancer
PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	PI3K Cascade IRS-mediated signalling GPVI-mediated activation cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K events in ERBB4 signaling PIP3 activates AKT signaling Interleukin-7 signaling Interleukin-7 signaling Signaling by SCF-KIT Synthesis of PIPs at the plasma membrane GAB1 signalosome Signaling by cytosolic FGFR1 fusion mutants Downstream signal transduction PI3K events in ERBB2 signaling PI3K/AKT activation Downstream TCR signaling Role of phospholipids in phagocytosis Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions Costimulation by the CD28 family CD28 dependent PI3K/Akt signaling G alpha (q) signalling events GP1b-IX-V activation signalling VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway Interleukin-3, Interleukin-5 and GM-CSF signaling Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PI3K/AKT signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer RET signaling Extra-nuclear estrogen signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Activated NTRK2 signals through PI3K Interleukin receptor SHC signaling Regulation of signaling by CBL Regulation of signaling by CBL Activated NTRK3 signals through PI3K FLT3 Signaling FLT3 Signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Isoprenaline SF1126 Enzastaurin Wortmannin
PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	PI3K Cascade IRS-mediated signalling GPVI-mediated activation cascade PIP3 activates AKT signaling Interleukin-7 signaling Interleukin-7 signaling Signaling by SCF-KIT Synthesis of PIPs at the plasma membrane Downstream signal transduction Rho GTPase cycle PI3K/AKT activation Downstream TCR signaling Role of phospholipids in phagocytosis Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions Costimulation by the CD28 family CD28 dependent PI3K/Akt signaling G alpha (q) signalling events VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway Interleukin-3, Interleukin-5 and GM-CSF signaling RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RET signaling Extra-nuclear estrogen signaling Interleukin receptor SHC signaling Regulation of signaling by CBL Regulation of signaling by CBL Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants	Isoprenaline SF1126
PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	GPVI-mediated activation cascade PIP3 activates AKT signaling Interleukin-7 signaling Interleukin-7 signaling Signaling by SCF-KIT Synthesis of PIPs at the plasma membrane Constitutive Signaling by Aberrant PI3K in Cancer Costimulation by the CD28 family CD28 dependent PI3K/Akt signaling G alpha (q) signalling events Interleukin-3, Interleukin-5 and GM-CSF signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RET signaling Extra-nuclear estrogen signaling Interleukin receptor SHC signaling Regulation of signaling by CBL Regulation of signaling by CBL Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	Isoprenaline SF1126
PLCG1	phospholipase C gamma 1	ISG15 antiviral mechanism Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PLCG1 events in ERBB2 signaling DAG and IP3 signaling PLC-gamma1 signalling Synthesis of IP3 and IP4 in the cytosol Downstream signal transduction Generation of second messenger molecules Role of phospholipids in phagocytosis Role of phospholipids in phagocytosis PECAM1 interactions EGFR interacts with phospholipase C-gamma DAP12 signaling FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization Role of second messengers in netrin-1 signaling VEGFR2 mediated cell proliferation VEGFR2 mediated cell proliferation Constitutive Signaling by EGFRvIII Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Phospholipase C-mediated cascade; FGFR3 Phospholipase C-mediated cascade; FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 point mutants in cancer RET signaling Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PLCG1 Erythropoietin activates Phospholipase C gamma (PLCG) Activated NTRK3 signals through PLCG1 Activated NTRK3 signals through PLCG1 FCGR3A-mediated IL10 synthesis Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants
PPM1L	protein phosphatase, Mg2+/Mn2+ dependent 1L	Sphingolipid de novo biosynthesis
PRDX2	peroxiredoxin 2	Detoxification of Reactive Oxygen Species TP53 Regulates Metabolic Genes Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	3-sulfino-L-alanine N-Carbamoyl-Alanine Copper
PTEN	phosphatase and tensin homolog	Synthesis of PIPs at the plasma membrane Synthesis of IP3 and IP4 in the cytosol Negative regulation of the PI3K/AKT network Downstream TCR signaling TP53 Regulates Metabolic Genes PTEN Loss of Function in Cancer Ub-specific processing proteases Ovarian tumor domain proteases Regulation of PTEN mRNA translation Regulation of PTEN localization Regulation of PTEN stability and activity Transcriptional Regulation by MECP2	Phosphatidylethanolamine	Vulvar cancer Prostate cancer Endometrial Cancer Glioma Small cell lung cancer Breast cancer Hepatocellular carcinoma Malignant melanoma
PTK2	protein tyrosine kinase 2	Apoptotic cleavage of cellular proteins Regulation of actin dynamics for phagocytic cup formation Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins NCAM signaling for neurite out-growth NCAM signaling for neurite out-growth Signal regulatory protein family interactions EPHB-mediated forward signaling EPHB-mediated forward signaling DCC mediated attractive signaling DCC mediated attractive signaling VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway RHO GTPases Activate WASPs and WAVEs RAF/MAP kinase cascade MET activates PTK2 signaling Extra-nuclear estrogen signaling Estrogen-dependent nuclear events downstream of ESR-membrane signaling FCGR3A-mediated phagocytosis	Endostatin 7-PYRIDIN-2-YL-N-(3,4,5-TRIMETHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE 2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE Fostamatinib
PTPN1	protein tyrosine phosphatase non-receptor type 1	Integrin signaling Negative regulation of MET activity Regulation of IFNG signaling PTK6 Down-Regulation MECP2 regulates neuronal receptors and channels Regulation of IFNA signaling Growth hormone receptor signaling Growth hormone receptor signaling	3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid 2-{[4-(2-Acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-YL]-oxalyl-amino}-benzoic acid 5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid, {4-[(2S)-2-({[(1S)-1-Carboxy-2-phenylethyl]carbamoyl}amino)-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid Compound 19 3-(4-{2-[2-(2-bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid 2-(Oxalyl-Amino)-Benzoic Acid {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid) Novo Nordisk a/S Compound N-(Bromoacetyl)-beta-alanyl-N-(2-{4-[(carboxycarbonyl)amino]phenyl}ethyl)-L-serinamide 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid PNU177836 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide (4S)-5-[[(2S)-1-[[(2S)-1-Amino-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-4-benzamido-5-oxopentanoic acid 4-[[(2S)-1-[[6-[(1-Amino-1-oxo-3-sulfanylpropan-2-yl)amino]-6-oxohexyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid L-cysteic acid 2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid 4-Carbamoyl-4-{[6-(Difluoro-Phosphono-Methyl)-Naphthalene-2-Carbonyl]-Amino}-Butyric Acid Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid 2-[{4-[(2S)-2-{[(Allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid N-(3-Carboxypropanoyl)-L-phenylalanyl-3-carboxy-O-(carboxymethyl)-N-pentyl-L-tyrosinamide 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID ISIS 113715 Trodusquemine Ertiprotafib 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID [(3S)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID 5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID 3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE [(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid 5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID ISOTHIAZOLIDINONE ANALOG 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid p-Benzoyl-L-phenylalanine 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER 5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid
PTPN11	protein tyrosine phosphatase non-receptor type 11	Interleukin-6 signaling PI3K Cascade MAPK3 (ERK1) activation MAPK1 (ERK2) activation GPVI-mediated activation cascade Prolactin receptor signaling PIP3 activates AKT signaling Spry regulation of FGF signaling Signaling by SCF-KIT GAB1 signalosome Downstream signal transduction PECAM1 interactions Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer Signaling by Leptin Costimulation by the CD28 family CTLA4 inhibitory signaling PD-1 signaling Signal regulatory protein family interactions Netrin mediated repulsion signals Platelet sensitization by LDL Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 FRS-mediated FGFR2 signaling FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Regulation of IFNG signaling RET signaling Interleukin-20 family signaling MET activates PTPN11 Regulation of RUNX1 Expression and Activity Interleukin-37 signaling Activated NTRK2 signals through FRS2 and FRS3 Interferon alpha/beta signaling Regulation of IFNA signaling Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon FLT3 Signaling STAT5 Activation STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants	Dodecyltrimethylammonium	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Metachondromatosis
PTPN2	protein tyrosine phosphatase non-receptor type 2	Negative regulation of MET activity Interleukin-37 signaling		Type I diabetes mellitus
PTPN6	protein tyrosine phosphatase non-receptor type 6	GPVI-mediated activation cascade Regulation of KIT signaling PECAM1 interactions Costimulation by the CD28 family PD-1 signaling Signal regulatory protein family interactions Platelet sensitization by LDL Interleukin-3, Interleukin-5 and GM-CSF signaling CD22 mediated BCR regulation Neutrophil degranulation Interferon gamma signaling Regulation of IFNG signaling Interleukin-37 signaling Interferon alpha/beta signaling Interleukin receptor SHC signaling Regulation of IFNA signaling Growth hormone receptor signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Tiludronic acid

Search Results for: PDGFRB